Document Detail

Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
MedLine Citation:
PMID:  15947596     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We compared biochemical progression rates measured by increasing prostate specific antigen (PSA) levels using a standard definition of biochemical recurrence among patients with screen detected prostate cancer treated with radical prostatectomy (RP) or radiotherapy (RT). MATERIALS AND METHODS: A total of 1,939 patients diagnosed with clinically localized prostate cancer in a community based screening study from 1989 to 1998, followed through 2001, were treated with RP or RT and agreed to enroll in a followup study. This prospective cohort study (median followup 62 months, range 0.2 to 141) used adjusted Cox proportional hazards models to examine time to progression. Selection bias was addressed with propensity scores. Biochemical evidence of cancer progression was defined as PSA greater than 0.2 ng/ml in patients who underwent RP and 3 consecutive PSA increases as recommended by the American Society for Therapeutic Radiology and Oncology criteria for radiotherapy. RESULTS: Of the patients 17% had evidence of cancer progression. The percentage with progression-free survival at 5 and 9 years for RP was 84% and 76%, respectively, and for RT 80% and 70%, respectively. Cox proportional hazards models produced a hazard ratio of 1.63 (95% CI, 1.12, 2.38) for RT compared with RP, adjusting for clinical stage, Gleason grade, preoperative PSA, biopsy age, treatment year and propensity for treatment type. CONCLUSIONS: With intermediate term followup, patients treated with RT were more likely to have cancer progression than with RP adjusting for demographics, clinical factors, selection bias and treatment year.
Julie M Krygiel; Deborah S Smith; Sharon M Homan; Walton Sumner; Robert F Nease; Ross C Brownson; William J Catalona
Related Documents :
10803836 - Failure pattern implications following external beam irradiation of prostate cancer: lo...
12834556 - Influence of the diagnostic modality on the pathological stage of clinically localized ...
12670556 - Serum prostate-specific antigen and survival after external beam radiotherapy for carci...
10394406 - Conformal proton beam therapy of prostate cancer--update on the loma linda university m...
15110446 - Literature-based recommendations for treatment planning and execution in high-dose radi...
23417896 - Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of urology     Volume:  174     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-06-10     Completed Date:  2005-07-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  126-30     Citation Subset:  AIM; IM    
Waterman Research Solutions, St. Louis, Missouri, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Disease-Free Survival
Mass Screening
Middle Aged
Prospective Studies
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood*,  diagnosis,  radiotherapy,  therapy*
Reg. No./Substance:
EC Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized st...
Next Document:  Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese pati...